GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GLPG-5201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GLPG-5201 overview

GLPG-5201 is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or relapsed or refractory small lymphocytic lymphoma (SLL), with or without Richter transformation (RT). It is administered through intravenous route. The therapeutic candidate comprises T cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing CD19 and 4-1BB.

Galapagos overview

Galapagos is a clinical-stage biotechnology company that specializes in the discovery and development of small-molecule medicines. The company conducts clinical trials in several areas, including inflammatory indications, cystic fibrosis, fibrosis and osteoarthritis. Its pipeline products include 5101, 5201, 5301 and 3667 for the indications of non-hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, systemic lupus erythematosus, dermatomyositis and other rare diseases. Galapagos collaborates with various partners and alliances to accelerate pipeline development. It operates in Belgium, the Netherlands, the US, Switzerland, France, Germany, Finland, Norway, Austria and Ireland, among others. Galapagos is headquartered in Mechelen, Belgium.

For a complete picture of GLPG-5201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.